First-trimester prediction of gestational diabetes mellitus using resistin, chemerin, progranulin, omentin, and IL-10

The study aims to evaluate the prediction of gestational diabetes mellitus (GDM) by proinflammatory resistin, chemerin, and progranulin, as well as anti-inflammatory adipokines omentin and IL-10, in maternal serum during the first trimester.

This prospective case-control study was performed in the obstetric unit of the university hospital from January 2023 to July 2024. Maternal serum samples from the study cases were collected during the first-trimester screening test to analyze resistin, chemerin, progranulin, omentin, and IL-10 levels. The cases were subsequently categorized into groups diagnosed with GDM and those not diagnosed between 24 and 28 weeks. Clinical and laboratory assessments were conducted.

The study included a total of 160 pregnant women. 38 of these patients had GDM, and 122 had control cases. In the serum samples taken in the first trimester, resistin, chemerin, and IL-10 levels did not create a statistically significant difference in the GDM and control groups (p > 0.05). Statistical differences were observed between the groups in progranulin and omentin levels (p = 0.042, p = 0.004, respectively). For predicting GDM, the optimum cut-off value was 83.5 for progranulin (sensitivity: 57.9 %, specificity: 63.9 %, PPV: 33.3 %, NPV: 83 %) and 2.5 for omentin (sensitivity: 73.7 %, specificity: 58.2 %, PPV: 35.4 %, NPV: 87.7 %).

First-trimester progranulin and omentin levels may be useful in excluding GDM, but they lack sufficient power to diagnose it.